Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price […]
More Stories
Mizuho Issues Pessimistic Forecast for Valero Energy (NYSE:VLO) Stock Price
Valero Energy (NYSE:VLO – Get Free Report) had its price target dropped by Mizuho from $165.00 to $158.00 in a...
Morgan Stanley Forecasts Strong Price Appreciation for Carnival Co. & (NYSE:CCL) Stock
Carnival Co. & (NYSE:CCL – Get Free Report) had its target price lifted by investment analysts at Morgan Stanley from...
Regency Centers (NASDAQ:REG) Price Target Raised to $80.00 at Mizuho
Regency Centers (NASDAQ:REG – Get Free Report) had its target price boosted by research analysts at Mizuho from $78.00 to...
Two Harbors Investment (NYSE:TWO) Hits New 52-Week Low – What’s Next?
Two Harbors Investment Corp. (NYSE:TWO – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday...
Boston Scientific (NYSE:BSX) Shares Gap Up – Should You Buy?
Shares of Boston Scientific Co. (NYSE:BSX – Get Free Report) gapped up before the market opened on Wednesday . The...
Sturm, Ruger & Company, Inc. (NYSE:RGR) Reaches New 52-Week Low – What’s Next?
Sturm, Ruger & Company, Inc. (NYSE:RGR – Get Free Report)’s share price reached a new 52-week low during mid-day trading...